CCRN CROSS COUNTRY HEALTHCARE INC

Overview and Growth

CROSS COUNTRY HEALTHCARE INC generated $1.05B of revenue in fiscal 2025, with net loss of $94.85M and an operating cash inflow of $48.25M. The $1.05B revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. The top line contracted 21.6% from $1.34B in fiscal 2024; this top-line contraction left the company with a smaller revenue base. Diluted earnings per share were -$2.93, translating the period’s attributable earnings into the amount reported for each diluted share. The diluted weighted-average share count was 32.41M, linking total earnings with the per-share result received by shareholders. Total assets stood at $448.95M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Asset turnover was 2.35x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

Operations produced a $84.41M operating loss before non-operating and tax effects. The operating loss equaled 8.0% of revenue, showing the scale of the operating deficit relative to sales. The company ended the period with a net loss of $94.85M, extending the operating result through all remaining items. The net loss equaled 9.0% of revenue, showing the bottom-line deficit relative to the company’s sales base. EBITDA was negative $67.62M, showing a deficit before interest, taxes, depreciation, and amortization. The company reported a pretax loss of $83.51M, before the effect of income taxes. Pretax margin was -7.9%, reflecting a pre-tax loss equal to 7.9% of revenue. Income tax expense totaled $11.34M, providing the reported tax component that separates pretax and after-tax earnings. The loss-to-equity relationship was 29.4%, placing the bottom-line deficit against shareholder capital. The loss-to-assets relationship was 21.1%, placing the bottom-line deficit against the company’s resource base. The bottom-line deficit increased from $14.56M in fiscal 2024 to $94.85M.

Liquidity and Capital Structure

The company held $448.95M of assets against $126.13M of liabilities and $322.82M of equity, revealing how the asset base was financed. At period end, current assets of $293.59M compared with current liabilities of $77.76M, defining the company’s short-term resource position. At 3.78x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Reported cash and equivalents were $108.74M, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 139.8%, excluding receivables and other current assets. Equity equaled 71.9% of assets, showing the shareholder-capital layer within the company’s balance sheet. Relative to total assets, liabilities measured 28.1%, complementing the separate equity-based view of the company’s capital structure. Measured against total assets, cash and equivalents represented 24.2%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $589.25M in fiscal 2024, the current asset base moved 23.8% and finished lower. Reported equity changed 22.9% from $418.96M in fiscal 2024, placing the current capital base lower year over year. The reported cash balance changed 33.2% from $81.63M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

The company reported $48.25M of operating cash flow, a cash inflow that shows the cash generated by operations. The cash-flow statement records $8.16M of capital expenditures, the investment amount considered after operating cash generation. Capital spending absorbed 16.9% of operating cash flow, quantifying the share of cash from operations directed to investment. Free cash flow came to $40.09M, leaving a positive amount after capital expenditures. Relative to revenue, free cash flow equaled 3.8%, showing how much sales converted into cash after investment. The free-cash-flow-to-assets relationship was 8.9%, comparing post-investment cash with the balance-sheet asset base.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.